\nSensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended September 30, 2026.<\/p>\n
Highlights included:<\/b><\/p>\n Management Commentary<\/b><\/p>\n \n“Our third quarter results reflect continued progress in building a broader, more diversified customer base and advancing our business toward sustainable profitability,” said Joseph Sardano, Chairman and Chief Executive Officer. \u201cWith dedicated reimbursement codes now in effect, our conversations with physicians are increasingly focused on how to bring SRT into their practices.<\/p>\n \n\u201cOur vision is to make SRT a more widely understood and accessible non-invasive treatment option for appropriate patients with non-melanoma skin cancer. We are expanding physician education and patient awareness, including through TreatSkinCancer.com<\/a>, while pursuing opportunities internationally and developing additional revenue streams tied to system utilization, software and services. The recent sale of our 1,000th SRT system is a milestone I am particularly proud of.<\/p>\n \n\u201cWe have spent years advancing the technology and growing our installed base. Today, we have a reimbursement framework that we believe can support broader adoption and a more scalable business. Our focus is on converting these opportunities into sales, increasing utilization and building a more diversified, sustainably profitable business,\u201d concluded Sardano.<\/p>\n Third Quarter 2026 Financial Results<\/b><\/p>\n \nRevenues were $6.0 million compared with $6.9 million for the quarter ended September 30, 2025, a decrease of $0.9 million, or 13.0%. The revenue decrease primarily reflected a shift in product mix toward lower-priced SRT-100 systems versus higher-priced SRT-100 Vision systems, resulting in a lower average selling price per unit, as well as the absence of sales to a historically large customer. In addition, three systems shipped during the quarter were under the Fair Deal Agreement program and rental arrangements compared to zero in the prior year period, for which revenue is recognized over the term of the agreement rather than at the time of shipment.<\/p>\n \nUnit shipments increased year-over-year to 26 systems, including eight carried over from the second quarter of 2026, compared with 16 systems in the prior-year period.<\/p>\n \nCost of sales was $2.7 million compared to $4.2 million for the quarter ended September 30, 2025, a decrease of $1.5 million, or 35.7%. The decrease in cost of sales was primarily related to the product mix, including a higher proportion of SRT-100 units shipped compared to SRT-100 Vision units shipped, as SRT-100 units have a lower average cost per unit.<\/p>\n \nGross profit was $3.3 million compared to $2.7 million for the three months ended September 30, 2025, an increase of $0.6 million, or 22.2%. Overall gross profit percentage was 55%, compared to 39.1% in the corresponding period in 2025. The increase in gross profit and margin was primarily driven by product mix, including a higher proportion of shipments of higher-margin SRT-100 units compared to lower-margin SRT-100 Vision units.<\/p>\n \nGeneral and administrative expense was $2.3 million compared to $1.9 million for the quarter ended September 30, 2025, an increase of $0.4 million, or 21.1%. The net increase in general and administrative expense was primarily due to higher legal and professional fees offset by reduction of insurance cost.<\/p>\n \nSelling and marketing expense was $1.5 million, flat with the third quarter of 2025.<\/p>\n \nResearch and development expense was $1.1 million compared to $1.8 million for the quarter ended September 30, 2025, a decrease of $0.7 million, or 38.9%. The decrease was primarily due to a reduction in lobbying cost and reduced headcount.<\/p>\n \nOther income of $0.1 million and $0.2 million for the quarters ended September 30, 2026 and 2025, respectively, relates primarily to interest income.<\/p>\n \nNet loss was $1.5 million, or $0.09 per share, compared with net loss of $0.9 million, or $0.06 per share, for the three months ended September 30, 2025.<\/p>\n \nAdjusted EBITDA was a negative $1.5 million, compared with negative $2.4 million for the third quarter of 2025. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial measures are provided.<\/p>\n \nCash, restricted cash and cash equivalents were $12.9 million as of September 30, 2026, compared with $15.2 million as of June 30, 2026. The Company had no outstanding borrowings under its revolving line of credit at September 30, 2026. Prepaid inventory was zero compared with $0.6 million as of June 30, 2026. Inventories were $18.0 million compared with $18.5 million as of June 30, 2026.<\/p>\n Conference Call and Webcast<\/b><\/p>\n \nSensus Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss these financial results, provide a business update and answer questions.<\/p>\n \nParticipants are encouraged to pre-register for the conference call using this link<\/a> to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call.<\/p>\n \nThe call will be webcast live and can be accessed at this link<\/a> or in the Investor Relations section of the Company\u2019s website at www.sensushealthcare.com<\/a>.<\/p>\n Use of Non-GAAP Financial Information<\/b><\/p>\n \nThis press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). Sensus Healthcare management understands that investors and analysts use Adjusted EBITDA, a non-GAAP financial measure, in analyzing the Company\u2019s performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.<\/p>\n SENSUS HEALTHCARE, INC. For the Three Months Ended<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n For the Nine Months Ended<\/b><\/p>\n<\/td>\n<\/tr>\n \u00a0September 30,<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0September 30,<\/b><\/p>\n<\/td>\n<\/tr>\n \u00a0<\/b><\/p>\n<\/td>\n 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n(1,493<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(943<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(12,868<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(4,552<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n81<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n98<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n263<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n283<\/p>\n<\/td>\n \n70<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n73<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n209<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0\u00a0 219<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(1,466<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n4,079<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 (2,079<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0 (126<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0 (160<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(368<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(528<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0 (1,468<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(2,398<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(8,685<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(6,657<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0About Sensus Healthcare<\/b><\/p>\n \nSensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com<\/a>.<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nThis press release includes statements that are, or may be deemed, \u201cforward-looking statements.\u201d In some cases, these statements can be identified by the use of forward-looking terminology such as \u201cbelieves,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201capproximately,\u201d or \u201cpotential,\u201d or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare, Inc., our industry, and\/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this release as a result of the following factors, among others: the level and availability of government and\/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries, including ongoing geopolitical tensions between the U.S. and China; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation (including the possibility of tariffs and fluctuations in tariffs on equipment we export or materials we import), or other aspects of our business; the performance of the Company\u2019s information technology systems and its ability to maintain data security; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission. To date, geopolitical uncertainties have not had any significant impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable. Any forward-looking statements that we make in this release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date this release is filed, except as may be required by applicable law.<\/p>\n SENSUS HEALTHCARE, INC. For the Three Months Ended<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n For the Nine Months Ended<\/b><\/p>\n<\/td>\n<\/tr>\n September 30,<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n September 30,<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n (unaudited)<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n (unaudited)<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n (unaudited)<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n (unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0$<\/p>\n<\/td>\n \n\u00a0 5,995<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n6,884<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n11,679<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n22,543<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 2,707<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n4,171<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 6,632<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n12,573<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n3,288<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,713<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n5,047<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n9,970<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n2,253<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,917<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 6,079<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n6,111<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 1,548<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,546<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 4,319<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n5,122<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 1,106<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,819<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,806<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n5,896<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n4,907<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n5,282<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n14,204<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n17,129<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 (1,619<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(2,569<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(9,157<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(7,159<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n126<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n160<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n368<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n528<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 126<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n160<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n368<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n528<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0\u00a0 (1,493<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(2,409<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(8,789<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(6,631<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 –<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(1,466<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n4,079<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(2,079<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0$<\/p>\n<\/td>\n \n\u00a0 (1,493<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n(943<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n(12,868<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n(4,552<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0$<\/p>\n<\/td>\n \n(0.09<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n(0.06<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n(0.78<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n(0.28<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0$<\/p>\n<\/td>\n \n(0.09<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n\u00a0 (0.06<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n(0.78<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0$<\/p>\n<\/td>\n \n\u00a0 (0.28<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 16,462,059<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16,320,036<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16,462,255<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16,327,233<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n16,462,059<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16,320,036<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16,462,255<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16,327,233<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n SENSUS HEALTHCARE, INC. As of September 30,<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n As of December 31,<\/b><\/p>\n<\/td>\n<\/tr>\n 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n<\/tr>\n (unaudited)<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0 12,920<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0\u00a0 22,083<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0 1,403<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0 6,041<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0 17,965<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 14,563<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0 –<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 1,522<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0 609<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0 –<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1,687<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1683<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0 34,584<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 45,892<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0 2,662<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,976<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0 –<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n4,079<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 265<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n452<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 2,731<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n352<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 309<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n288<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0 40,551<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n53,039<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0 3,746<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 3,343<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 302<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0\u00a0 275<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0 278<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 262<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 785<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0842<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0 5,111<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 4,722<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0 –<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 209<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0 –<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 10<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5,111<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0 4,941<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0–<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0 169<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0169<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0 46,300<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0\u00a0 46,090<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0 (3,876<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0 (3,876<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0 (7,153<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n5,715<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0 35,440<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n48,098<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a040,551<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n53,039<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20261112617659\/en\/<\/a><\/span><\/p>\n\n
\n
\n \n
\n
GAAP TO NON-GAAP RECONCILIATION
\n
(unaudited)<\/b>\u00a0<\/p>\n<\/td>\n<\/tr>\n\n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n (in thousands)<\/i><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0Net loss, as reported\u00a0<\/b><\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n \u00a0Add:\u00a0<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Depreciation\u00a0<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Stock compensation expense\u00a0<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Income tax (benefit) expense\u00a0\u00a0<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Interest income, net\u00a0<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0Adjusted EBITDA, non-GAAP\u00a0<\/b><\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n \u00a0<\/td>\n<\/tr>\n<\/table>\n \n
\n \u00a0<\/td>\n<\/tr>\n \n \u00a0<\/td>\n<\/tr>\n \n \u00a0<\/td>\n<\/tr>\n \n \n
\n
CONSOLIDATED STATEMENTS OF OPERATIONS<\/b>\u00a0<\/p>\n<\/td>\n<\/tr>\n\n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \u00a0<\/b><\/td>\n \n \n \n \n (in thousands, except shares and per share data)<\/i><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0\u00a0<\/b><\/td>\n \n \n \n \n \n \n \n \n \n Revenues<\/b><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Cost of sales<\/b><\/td>\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \n Gross profit<\/b><\/td>\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \n Operating expenses:<\/b><\/td>\n \n \u00a0\u00a0\u00a0\u00a0<\/td>\n \n \n \n \u00a0\u00a0\u00a0\u00a0<\/td>\n \n <\/tr>\n \n General and administrative<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Selling and marketing<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Research and development<\/td>\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \n Total operating expenses<\/b><\/td>\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \n Loss from operations<\/b><\/td>\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \n Other income:<\/b><\/td>\n \n \u00a0\u00a0\u00a0\u00a0<\/td>\n \n \u00a0\u00a0\u00a0\u00a0<\/td>\n \n \u00a0\u00a0\u00a0\u00a0<\/td>\n \n \u00a0\u00a0\u00a0\u00a0<\/td>\n<\/tr>\n \n Interest income, net<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Other income, net<\/b><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Loss before income tax<\/b><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Provision for (benefit from) income taxes<\/td>\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \n Net loss<\/b><\/td>\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n \n \n \n \n \n \n \n \n Net loss per share \u2013 basic<\/b><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n diluted<\/b><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Weighted average number of shares used in computing net loss per share\u00a0 \u2013 basic<\/b><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n diluted\u00a0<\/b><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \u00a0<\/td>\n<\/tr>\n \n \u00a0<\/td>\n<\/tr>\n \n \u00a0<\/td>\n<\/tr>\n \n \u00a0<\/td>\n<\/tr>\n \n \n
\n
CONSOLIDATED BALANCE SHEETS<\/b>\u00a0<\/p>\n<\/td>\n<\/tr>\n\n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n (in thousands, except shares and per share data)<\/i><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n Assets<\/b><\/td>\n \n \n \n \n \n <\/tr>\n \n Current assets<\/b><\/td>\n \n \n \n \n \n <\/tr>\n \n Cash, restricted cash, and cash equivalents<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n Accounts receivable, net<\/td>\n \n \n \n \n \n \n \n \n \n Inventories<\/td>\n \n \n \n \n \n \n \n \n \n Prepaid inventory<\/td>\n \n \n \n \n \n \n \n \n \n Notes receivable, current portion<\/td>\n \n \n \n \n \n \n \n \n \n Other current assets<\/td>\n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n Total current assets<\/b><\/td>\n \n \n \n \n \n \n \n \n \n Property and equipment, net<\/td>\n \n \n \n \n \n \n \n \n \n Deferred tax asset<\/td>\n \n \n \n \n \n \n \n \n \n Operating lease right-of-use assets, net<\/td>\n \n \n \n \n \n \n \n \n \n Notes receivable, net of current portion<\/td>\n \n \n \n \n \n \n \n \n \n Other noncurrent assets<\/td>\n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n Total assets<\/b><\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n Liabilities and stockholders\u2019 equity<\/b><\/td>\n \n \n \n \n \u00a0<\/td>\n <\/tr>\n \n Current liabilities<\/b><\/td>\n \n \n \n \n \n <\/tr>\n \n Accounts payable and accrued expenses<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n Product warranties<\/td>\n \n \n \n \n \n \n \n \n \n Operating lease liabilities, current portion<\/td>\n \n \n \n \n \n \n \n \n \n Deferred revenue, current portion<\/td>\n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n Total current liabilities<\/b><\/td>\n \n \n \n \n \n \u00a0<\/td>\n \n \n \n Operating lease liabilities, net of current portion<\/td>\n \n \n \n \n \n \n \n \n \n Deferred revenue, net of current portion<\/td>\n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n Total liabilities<\/b><\/td>\n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n Commitments and contingencies<\/b><\/td>\n \n \n \n \n \u00a0<\/td>\n <\/tr>\n \n Stockholders\u2019 equity<\/b><\/td>\n \n \n \n \n \n <\/tr>\n \n Preferred stock, 5,000,000 shares authorized and none issued and outstanding<\/td>\n \n \n \n \n \n \n \n \n \n Common stock, $0.01 par value \u2013 50,000,000 authorized; 17,055,095 issued and 16,462,059 outstanding at September 30, 2026;\u00a0 17,056,845 issued and 16,463,809 outstanding at December 31, 2025<\/td>\n \n \n \n \n \n \n \n \n \n Additional paid-in capital<\/td>\n \n \n \n \n \n \n \n \n \n Treasury stock, 593,036 shares at cost, at September 30, 2026 and December 31, 2025<\/td>\n \n \n \n \n \n \n \n \n \n (Accumulated deficit) retained earnings<\/td>\n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n Total stockholders\u2019 equity<\/b><\/td>\n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n Total liabilities and stockholders\u2019 equity<\/b><\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n<\/table>\n <\/p>\n